Exercise, age, and bones.

W C Thomas

Home/Archive/PubMed

PubMed · 8178198

Exercise, age, and bones.

W C Thomas

View original source ↗Export metadata ↓

Abstract

Skeletal development in average healthy individuals is maximal at age 25 in women and at age 30 to 35 in men. However, there are significant racial differences, skeletal mass being greater in black than in white individuals. This difference appears best accounted for by increased muscle mass in blacks. Bed rest, immobilization, weightlessness (as in space flights), and aging induce a decrease in skeletal mass. The degree of osteopenia in the elderly depends partly on skeletal development during formative years and can be prevented from becoming severe by maintaining good nutritional status (calcium, vitamin D, protein) and physical activity. Maintenance or actual increase in muscle mass is a desired effect of appropriate physical activity, but excessive physical exercise may induce estrogen deficiency and menstrual irregularities in premenopausal women. In addition to diet and exercise, pharmacologic therapy (estrogens, androgens, diphosphonates, or calcitonin) is indicated in patients with significant osteoporosis.

Explore related subjects

Absorptiometry, Photon Adult Aging Bone Density Bone and Bones Cushing Syndrome Diet Exercise Female Humans Male Middle Aged Osteoporosis Racial Groups Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

W C Thomas. 1994. Exercise, age, and bones.. https://pubmed.ncbi.nlm.nih.gov/8178198/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A repeated measures concordance correlation coefficient.

The concordance correlation coefficient is commonly used to assess agreement between two raters or two methods of measuring a response when the data are measured on a continuous scale. However, the situation may arise in which repeated measurements are taken for each rater or method, e.g. longitudinal studies in clinical trials or bioassay data with subsamples. This paper proposes a coefficient for measuring agreement between two raters or two methods of measuring a response in the presence of repeated measurements. We illustrate the methodology with examples comparing (1) 1-hr versus 2-hr blood draws for measuring cortisol in an asthma clinical trial and (2) two measurements of percentage body fat, from skinfold calipers and dual energy X-ray absorptiometry.

Absorptiometry, Photon↗

PubMed2007

Crystallization and preliminary X-ray analysis of a domain in the Runx2 transcription factor that interacts with the 1alpha,25 dihydroxy vitamin D3 receptor.

The Runx2 transcription factor is a key regulator of osteoblast differentiation. In response to 1alpha,25 dihydroxy vitamin D3, Runx2 may interact with the 1alpha,25 dihydroxy vitamin D3 receptor (VDR) in the promoter of target genes, producing a synergic activation of their transcription. Previous studies have suggested that the motifs responsible for the VDR-Runx2 interaction are contained within the 230-361 domain of Runx2. In this work, we confirmed by GST-pull down that Runx2(I(209-361)) is sufficient to interact with the VDR. To obtain structural information, GST-Runx2(I(209-361)) protein was overexpressed in Escherichia coli, purified and crystallized using the hanging-drop vapor-diffusion method and polyethyleneglycol as a precipitant. The crystals were found to diffract to a maximum resolution of 2.7 A and a complete data set to a 3.3 A resolution was collected and analyzed. The crystals belong to the tetragonal system, with a space group P4 and unit-cell parameters of a = b = 90.8, and c = 57.2 A. The presence of a monomer of the recombinant GST-Runx2(I(209-361)) in the asymmetric unit gives a V(M) of 2.7 A(3) Da(-1) and a solvent content of 54.8%.

Absorptiometry, Photon↗

PubMed2007

Quantifying the treatment effect explained by markers in the presence of measurement error.

Surrogate markers or intermediate markers are important in identifying subjects with high risk of a serious disease or for monitoring disease progression of a subject on treatment. Quantifying the proportion of treatment effect (PTE) explained by markers has been studied extensively. Due to reasons such as biological variation, limited machine precision, etc. markers are generally measured with error. The estimated PTE ignoring the measurement error could be biased, which may lead to incorrect conclusions. In this article, we adjust for the measurement error using regression calibration to construct a less biased estimator of excess relative odds, a quantity to measure the treatment effect explained by markers. The method is applied to data from a clinical study in osteoporosis.

Absorptiometry, Photon↗